Correct Answer: B. Oxidizes uric acid
Pegloticase is a recombinant uricase enzyme conjugated to polyethylene glycol (PEG), used in severe, refractory hyperuricemia and tumor lysis syndrome (TLS). The mechanism is oxidative conversion of uric acid to allantoin, a more soluble and readily excretable metabolite. Uricase catalyzes the enzymatic oxidation of uric acid (the end product of purine metabolism in humans) to allantoin, which is 5–10 times more soluble in urine and does not precipitate in renal tubules. This is critical in TLS, where massive cell death releases intracellular purines; rapid uric acid accumulation causes acute kidney injury (AKI) via crystal nephropathy. Pegloticase rapidly lowers serum uric acid (often within hours), preventing urate crystal deposition in kidneys, joints, and soft tissues. The PEG coating reduces immunogenicity and extends half-life. In Indian clinical practice, pegloticase is reserved for severe TLS (especially in hematologic malignancies like acute leukemias) when allopurinol and febuxostat fail or are contraindicated. It is not a first-line agent due to cost and immunogenicity risk, but it is the most potent uric acid-lowering drug available.
Why the other options are wrong
A. Hydrolysis of uric acid — This is wrong because pegloticase does not hydrolyze uric acid; it oxidizes it. Hydrolysis would break a chemical bond using water, but pegloticase catalyzes oxidation—transfer of electrons to oxygen—converting uric acid to allantoin. This is a common semantic trap; students may confuse enzymatic mechanisms if they do not understand the biochemistry of uricase. C. Xanthine oxidase inhibition — This is wrong because xanthine oxidase inhibition is the mechanism of allopurinol and febuxostat, not pegloticase. These drugs block the enzyme that produces uric acid from xanthine and hypoxanthine, reducing uric acid synthesis. Pegloticase works downstream—it degrades already-formed uric acid. This is a classic NBE trap: confusing drugs in the same therapeutic class (uric acid-lowering agents). D. URAT-1 receptor inhibition — This is wrong because URAT-1 inhibition is the mechanism of lesinurad and benzbromarone, which block renal urate reabsorption and increase urinary excretion. Pegloticase does not interact with URAT-1; it directly degrades circulating uric acid. This option tests whether students confuse uricosuric agents with uricase.
High-Yield Facts
- Pegloticase mechanism: oxidizes uric acid to allantoin (5–10× more soluble, readily excreted).
- Uricase: recombinant enzyme conjugated to PEG; half-life ~18 days; lowers serum uric acid within hours.
- Tumor lysis syndrome: massive cell death → hyperuricemia → acute kidney injury; pegloticase is DOC for severe, refractory cases.
- Allopurinol vs. pegloticase: allopurinol inhibits uric acid synthesis (xanthine oxidase); pegloticase degrades existing uric acid (oxidation).
- Immunogenicity risk: pegloticase can trigger anti-PEG antibodies and infusion reactions; not first-line due to cost and immunogenicity.
Mnemonics
PEG-loticase = Oxidase (not inhibitor) PEG = Polyethylene Glycol coating; loticase = uricase enzyme that oxidizes uric acid to allantoin. Remember: Pegloticase is an enzyme that works on uric acid (oxidation), not an inhibitor that blocks its synthesis. TLS Drug Ladder: Prevent → Block → Degrade
- 1.Prevent purine release (tumor control). 2. Block synthesis (allopurinol/febuxostat = xanthine oxidase inhibitors). 3. Degrade existing uric acid (pegloticase = uricase = oxidation). Use when steps 1–2 fail.
NBE Trap
NBE pairs pegloticase with other uric acid-lowering drugs (allopurinol, febuxostat, lesinurad) to trap students who confuse mechanisms: synthesis inhibition vs. degradation vs. renal excretion. The key discriminator is that pegloticase is the only one that directly oxidizes (degrades) uric acid.
Clinical Pearl
In Indian tertiary centers managing acute leukemia with TLS, pegloticase is reserved for patients with serum uric acid >12 mg/dL despite allopurinol + hydration, or those with AKI. A single infusion can drop uric acid by 60–80% within 24 hours, preventing dialysis-dependent renal failure—a life-saving intervention in resource-limited settings where dialysis capacity is limited.
_Reference: KD Tripathi Pharmacology Ch. 18 (Antigout drugs); Harrison Ch. 353 (Gout and related disorders)_